Recorded Presentations from the NCCN 2019 Congress Series™: Breast Cancer

Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The treatment of breast cancer is rapidly evolving. Results from numerous clinical trials continue to expand new therapeutic options, treatment and risk reduction strategies, and diagnostic/prognostic tools. Health care professionals need to be educated on current and emerging scientific data to make evidence-based treatment decisions and to provide optimal care for patients with breast cancer.

This congress will provide expert insights on the current standard of care for patients with breast cancer to assist oncology health care professionals with formulating breast cancer management strategies. Featured sessions at this program will include the latest clinical research updates presented at the 2018 San Antonio Breast Cancer Symposium^® (SABCS). This update has become the highlight of this congress hosted by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University each year.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other health care professionals who manage patients with breast cancer.

Learning Objectives

Following this program, participants should be able to:

Summarize the current standards of oncology care, key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®), and clinical research updates from the 2018 SABCS, and integrate appropriate strategies into clinical practice to optimize the management of patients with breast cancer and improve patient outcomes.
Evaluate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of patients with breast cancer.

Additional information

Supporters:

This activity is supported by educational grants from:

AstraZeneca
Genentech
Genomic Health, Inc.
Novartis
Pfizer

Course summary

Course opens:

03/18/2019

Course expires:

03/18/2020

Cost:

$0.00

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Full disclosure of faculty relationships will be made prior to the activity.

This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals.

Status

Price

Title

Locked

$0.00Included

Recorded Presentations from the NCCN 2019 Congress Series™: Breast Cancer